Cameroon vs Tajikistan: Average cost of drugs for extensively drug-resistant tuberculosis
Cameroon
227 constant 2022 US$
in 2024
Tajikistan
257 constant 2022 US$
in 2024
Cameroon rank
54th
Tajikistan rank
53rd
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Cameroon
- Tajikistan
How they compare
Tajikistan currently reports 257 constant 2022 US$ against 227 constant 2022 US$ in Cameroon, a difference of 30 constant 2022 US$.
That makes Tajikistan's figure about 1.1 times Cameroon's.
The two have swapped places 2 times across 8 shared years of data; in 2017 it was Tajikistan ahead.
Cameroon ranks 54th and Tajikistan ranks 53rd of 56 countries.
Across the 2 decades both report, Cameroon averaged higher in 1 and Tajikistan in 1.
Head to head by decade
| Decade | Cameroon | Tajikistan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 4,251 constant 2022 US$ | 4,438 constant 2022 US$ | 187 constant 2022 US$ | Tajikistan |
| 2020s | 2,687 constant 2022 US$ | 2,102 constant 2022 US$ | 584.8 constant 2022 US$ | Cameroon |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Cameroon or Tajikistan?
- Tajikistan, at 257 constant 2022 US$ against 227 constant 2022 US$ in Cameroon as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Cameroon and Tajikistan?
- 30 constant 2022 US$, with Tajikistan ahead.
- How many years of comparable data are there for Cameroon and Tajikistan?
- 8 years are reported by both, from 2017 to 2024.
- How do Cameroon and Tajikistan rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Cameroon ranks 54th and Tajikistan ranks 53rd of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.